LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that Dr. Rahul Singhvi has been appointed to the company’s Board of Directors. Dr. Singhvi is currently the President and Chief Executive Officer of Novavax, Inc. (NASDAQ: NVAX), a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. His appointment increases the number of independent directors to five.
